We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Administration Route for Remdesivir
News

New Administration Route for Remdesivir

New Administration Route for Remdesivir
News

New Administration Route for Remdesivir

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Administration Route for Remdesivir"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists at the University of North Carolina at Chapel Hill are testing a new route for remdesivir, a pill form of the COVID-19 treatment that could make it accessible for early treatment.


In laboratory tests, a modification of remdesivir was as effective as molnupiravir, another oral antiviral, at treating COVID-19 in mice. Further, the new drug compound can be adapted into a pill designed to halt coronaviruses before they multiply and cause severe disease.


The current form of remdesivir is given by injection. But an oral version could extend its reach and benefits to patients outside of the hospital, said Timothy Sheahan, a virologist at UNC Gillings School of Global Public Health and senior author of a new study in Science Translational Medicine.


“Oral antiviral medications have the potential to shorten the duration of disease, potentially diminish transmission and prevent hospitalization if taken early enough,” Sheahan said.


Remdesivir works by blocking the machinery the virus needs to make copies of itself and spread throughout the body.


The compound tested at UNC-Chapel Hill is a prodrug named GS-621763 which can quickly turn into remdesivir inside the body. It was most protective against SARS-CoV-2, the virus that causes COVID-19, but was also very effective against MERS-CoV, a related virus that leads to Middle East Respiratory Syndrome.

“We saw protective effects, like reduced lung damage, viral load in the lungs, and improved lung function in infected mice, when we administered the drug at 12 hours or even at 24 hours after infection in mice,” said lead study author Alexandra Schäfer, assistant professor of epidemiology at the UNC Gillings School of Global Public Health.


In early 2020, UNC-Chapel Hill virologist Ralph Baric and Gilead Sciences Inc. identified remdesivir as a potential COVID-19 treatment. For nearly two years, remdesivir has been used in hospitals to treat very sick patients with COVID-19.

While the drug has shown mixed results in clinical studies, it’s been surprisingly effective in treating patients early in the disease.


The results of using remdesivir early in the course of disease in outpatients were dramatic. A three-day course resulted in an 87% lower risk of hospitalization and death.


Additional study is needed of the compound’s safety and effectiveness, but the new study opens the door for remdesivir to take a place among the growing number of oral COVID-19 treatment options.


“Oral drugs that can be formulated as pills have potential to make a big impact on reducing the disease burden caused the COVID pandemic,” said David R. Martinez, a viral immunologist and postdoctoral researcher at UNC Gillings School of Global Public Health. “People can safely take a round of pills at home while in isolation, and reduce community spread.”


Research at UNC-Chapel Hill has been central to the nation’s response to the COVID-19 pandemic. Carolina research contributed to the speedy development of antiviral medicines and vaccines, and its scientists are designing a universal coronavirus vaccine that could prevent future pandemics.


The National Institutes of Health National Institute of Allergy and Infectious Disease and the North Carolina Policy Collaboratory helped fund the study conducted with scientists at Gilead Sciences Inc.


Reference: Schäfer A, Martinez DR, Won JJ, et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci. Transl. Med. 2022;0(0):eabm3410. doi: 10.1126/scitranslmed.abm3410


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement